comparemela.com

Page 11 - Todd Ellerin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MA experts say masking up this fall a good idea, but debate is healthy

FDA OKs plans for new COVID booster; Massachusetts vaccine rates high

Vaccinated, low-risk people won t benefit from COVID-19 pill Paxlovid: Pfizer study suggests - WEIS

Vaccinated, low-risk people won t benefit from COVID-19 pill Paxlovid: Pfizer study suggests - WEIS
weisradio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from weisradio.com Daily Mail and Mail on Sunday newspapers.

Vaccinated, low-risk people won t benefit from COVID-19 pill Paxlovid: Pfizer study suggests

Philipp von Ditfurth/picture alliance via Getty Images, FILE(WASHINGTON) Pfizer's COVID-19 treatment Paxlovid has been hailed as a breakthrough in the fight against COVID-19. The pills have shown to dramatically reduce the risk of being hospitalized or dying for people who are at high-risk of COVID-19. But mounting evidence suggests Paxlovid may not benefit everyone equally. The company recently announced the results of a new study that found the drug did not meaningfully benefit people without underlying medical conditions or no previous infection of COVID. This comes weeks after the Biden administration announced plans to purchase 20 million treatment courses of the drug as it focuses on the Test-to-Treat initiative as part of the National COVID-19 Preparedness Plan. Some infectious disease experts interviewed by ABC News said the new study could influence the way doctors prescribe the drug, potentially declining to prescribe it to vaccinated, otherwise healthy patients. But o

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.